HCA Healthcare reported a strong first quarter in 2023, with revenues increasing to $15.591 billion and net income attributable to HCA Healthcare, Inc. totaling $1.363 billion, or $4.85 per diluted share. The company saw increases in same facility admissions and equivalent admissions, reflecting strong demand for its services. HCA also repurchased 3.340 million shares of its common stock at a cost of $846 million and revised its 2023 guidance upwards.
Revenues totaled $15.591 billion, up from $14.945 billion in Q1 2022.
Net income attributable to HCA Healthcare, Inc. reached $1.363 billion, or $4.85 per diluted share, compared to $1.273 billion, or $4.14 per diluted share, in Q1 2022.
Adjusted EBITDA totaled $3.172 billion, compared to $2.944 billion in the first quarter of 2022.
Same facility admissions increased by 4.4 percent and same facility equivalent admissions increased by 7.5 percent compared to the prior year period.
HCA Healthcare revised its 2023 guidance upwards, with revenue expected to be in the range of $62.5 to $64.5 billion and EPS between $17.25 and $18.55.